Financial Performance - Total revenues and other income for the nine-month period ended September 30, 2024, increased to $34,052,000, compared to $7,203,000 for the same period in 2023, representing a significant growth[7]. - The net loss attributable to shareholders for the nine-month period ended September 30, 2024, was $42,683,000, compared to a net loss of $66,648,000 for the same period in 2023, reflecting a reduction in losses[7]. - The basic net loss per share attributable to shareholders for the nine-month period ended September 30, 2024, was $(0.49), compared to $(1.09) for the same period in 2023[7]. - For the nine-month period ended September 30, 2023, net income was a loss of $66,648 thousand, compared to a loss of $42,683 thousand in 2024, reflecting a significant decline[8]. - The company reported a comprehensive income loss of $41.156 million for the nine-month period ended September 30, 2024[13]. - The net loss for the nine-month period ended September 30, 2024, was $42.683 million, compared to a net loss of $59.264 million for the same period in 2023[13]. Cash and Liquidity - Cash and cash equivalents as of September 30, 2024, amounted to $159,087,000, an increase from $136,708,000 as of December 31, 2023[6]. - Cash and cash equivalents at the end of the period for the nine-month period ended September 30, 2023, were $67,358 thousand, increasing to $159,087 thousand in 2024, indicating improved liquidity[11]. - Cash and cash equivalents stood at $159.1 million, with an additional deposit of $100.3 million, providing sufficient funds to support operations into 2027[20]. Research and Development - Research and development expenses for the nine-month period ended September 30, 2024, were $69,670,000, up from $62,690,000 in 2023, indicating an increase of approximately 11.5%[7]. - Research and development expenses increased to $69.7 million for the nine-month period ended September 30, 2024, up from $62.7 million in 2023, reflecting a rise of approximately 11.9%[48]. - Research and development expenses for the three-month period ended September 30, 2023, were $19,075 thousand, increasing to $23,829 thousand in 2024, indicating a rise in investment in innovation[9]. - The total research and development expenses for Q3 2024 were $23,829 million, reflecting a significant investment in innovation and product development[52]. Assets and Liabilities - Total assets increased to $395,876,000 as of September 30, 2024, compared to $334,270,000 as of December 31, 2023, showing a growth of approximately 18.4%[6]. - Total current liabilities increased to $165,650,000 as of September 30, 2024, from $155,144,000 as of December 31, 2023, representing a rise of about 6.5%[6]. - Non-current financial liabilities increased to $61,575,000 as of September 30, 2024, from $49,125,000 as of December 31, 2023, reflecting an increase of about 25.3%[6]. - Total financial liabilities increased from $135,151 thousand as of December 31, 2023 to $141,003 thousand as of September 30, 2024[91]. - Total deferred revenues and contract liabilities increased by $11.7 million to $122.0 million from $110.3 million as of December 31, 2023, primarily due to additional invoicing related to three Research Plans[108]. Shareholder Equity - Total shareholders' equity increased to $129,424,000 as of September 30, 2024, from $84,695,000 as of December 31, 2023, indicating a growth of approximately 52.7%[6]. - As of September 30, 2024, Cellectis reported total shareholders' equity of $129.424 million, an increase from $76.123 million as of September 30, 2023[13]. - The share capital increased to $5.9 million as of September 30, 2024, from $4.4 million as of January 1, 2024, following a capital increase involving the issuance of 28 million shares for $140.0 million[110]. - Cellectis' share capital increased to 100,093,873 shares as of September 30, 2024, up from 55,583,768 shares as of September 30, 2023[13]. Collaboration and Agreements - Cellectis entered into a Joint Research and Collaboration Agreement with AstraZeneca, aiming to develop up to 10 novel cell and gene therapy products[27]. - AstraZeneca made an initial equity investment of $80 million, acquiring approximately 22% of Cellectis' share capital[28]. - Cellectis received an upfront payment of $25 million under the Joint Research Collaboration Agreement, with potential milestone payments ranging from $70 million to $220 million for each candidate product[28]. - The total upfront payments allocated to Research Plans amount to $109.1 million, including $25 million from the AZ JRCA and $48.4 million from the Subsequent Investment Agreement[36]. Financial Income and Expenses - The company reported a financial income of $29,727,000 for the nine-month period ended September 30, 2024, compared to $16,133,000 for the same period in 2023, marking an increase of approximately 84.5%[7]. - Financial income for the nine-month period ended September 30, 2024 was $29,727 million, up from $16,133 million in the same period of 2023, marking an increase of 84.5%[58]. - Financial expenses increased from $23,085 million in the nine-month period ended September 30, 2023 to $24,049 million in 2024, a rise of 4.2%[58]. - The company reported a foreign exchange gain of $12,424 million in the nine-month period ended September 30, 2023, which decreased to $3,811 million in 2024, a decline of 69.4%[58]. Stock Options and Compensation - The weighted-average fair value of stock options granted decreased to €1.41 in 2024 from €1.65 in 2023, with expected volatility remaining high at 64.6%-65.2%[113]. - Share-based compensation expense related to stock option awards was $1.8 million for the nine-month period ended September 30, 2024, compared to $2.0 million for the same period in 2023[115]. - The total number of shares outstanding increased to 100,093,873 as of September 30, 2024, reflecting the issuance of shares related to capital increases and employee stock options[110]. - The balance of non-employee warrants as of September 30, 2024, was 359,207, with a weighted-average exercise price of €26.69 and a remaining average useful life of 1.7 years[120].

UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderAppointed Adrian Kilcoyne, M.D., MPH, MBA, an industry leader in the advancement of cell therapy treatment, as Chief Medical OfficerCash position of $264 million as of September ...

Core Points - Cellectis, a clinical-stage biotechnology company, will report its financial results for Q3 2024 on November 4, 2024, after the US market closes [1] - An investor conference call and webcast will take place on November 5, 2024, at 8:00 AM ET, discussing the Q3 results and business updates [2] - Cellectis specializes in gene-editing technologies, particularly in developing CAR-T immunotherapies and therapeutic gene editing for various diseases [2] Company Overview - Cellectis utilizes an allogeneic approach for CAR-T immunotherapies, focusing on off-the-shelf gene-edited CAR T-cells for cancer treatment [2] - The company has 25 years of experience in gene editing and employs TALEN® technology and PulseAgile electroporation system [2] - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, and is listed on Nasdaq and Euronext Growth [2]

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that they will be showcasing pre-clinical data that permit the design of an efficient and specific TALE base editors (TALEB) as well as a process to enhance the efficacy of non-viral gene insertion in hematopoietic stem and progenitor cells (HSPCs) at the ...

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published a scientific article in Science Advances suggesting that TALEN®-edited MUC1 CAR T-cells could be a potential treatment option for advance-stage triple negative breast cancer (TNBC) patients with limited therapeutic options. Globally, breast cancer contin ...

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published an article in Molecular Therapy demonstrating TALEN®-mediated gene editing capabilities for design of SMART DUAL CAR T-cells, which efficiently target immunotherapy recalcitrant solid tumors while mitigating potential safety risks. Adoptive cell therapy b ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately. "We're thrilled to welcome Dr. Kilcoyne to Cellectis. He is a strategic, forward-thinking drug developer who is passionate about delivering life-sa ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately. "We're thrilled to welcome Dr. Kilcoyne to Cellectis. He is a strategic, forward-thinking drug developer who is passionate about delivering life-sa ...

Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and six month periods ended June 30, 2024, included herein, have been prepared in accordance with International Accounting Standard 34 ("IAS 34")– Interim Financial Reporting as issued by the International Accounting Standards Board ("IASB"). The consolidated financial statements are presented in U.S. dollars. All references in this interim report to "$" and "U.S. dollars" mean U.S. dollars and all referenc ...

ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL ODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatment Cash position of $273 million as of June 30, 20241; cash runway projection into 2026 ________________________ NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and g ...